Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 1/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.50 |
| ▸ | PRKCG | P05129 | 3/20 | 0.50 |
| ▸ | PRKCB | P05771 | 3/20 | 0.50 |
| ▸ | PRKCA | P17252 | 3/20 | 0.50 |
| ▸ | PRKCH | P24723 | 3/20 | 0.50 |
| ▸ | PRKCI | P41743 | 3/20 | 0.50 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.50 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.50 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.50 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.50 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.50 |
| ▸ | PRKACA | P17612 | 2/20 | 0.50 |
| ▸ | PRKACG | P22612 | 2/20 | 0.50 |
| ▸ | PRKACB | P22694 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL117620 | 0.87 | KCNA5 (0.59) | KCNA5PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL7429623 | 0.83 | PRKD3 (0.56) | KCNA5PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL116779 | 0.82 | KCNA5 (0.49) | KCNA5CYP3A4TRPV1 | |
| SCHEMBL7439438 | 0.82 | PRKD3 (0.52) | KCNA5PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL9880964 | 0.79 | PRKCG (0.62) | KCNA5PRKD3PRKCGPRKCBPRKCA | |
| SCHEMBL29695256 | 0.79 | PRKCG (0.66) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL5665350 | 0.79 | PRKCG (0.66) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL5664219 | 0.77 | PRKCG (0.60) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL5665334 | 0.77 | PRKD3 (0.55) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL5662531 | 0.77 | PRKD3 (0.54) | PRKD3PRKCGPRKCBPRKCAPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. | 2012-05-31 | — | — | US | disclosed |
| EP-2424857-A1 | DUAL-ACTION INHIBITORS AND METHODS OF USING SAME | Aerie Pharmaceuticals, Inc. (US) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010127329-A1 | DUAL-ACTION INHIBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127329-A1 | DUAL-ACTION INHIBITORS AND METHODS OF USING SAME | AERIE PHARMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127330-A1 | DUAL-ACTION INHIBITORS AND METHODS OF USING SAME | AERIE PHAMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010127330-A1 | DUAL-ACTION INHIBITORS AND METHODS OF USING SAME | AERIE PHAMACEUTICALS, INC. (US) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135984-A1 | DUAL-ACTION INHBITORS AND METHODS OF USING SAME | SLC6A2, ROCK2, SLC6A4 | KCNA5 4028/4885PRKD3 1227/4885PRKCG 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.